Astra Data, Novavax Delay Spur Moderna Vaccine Demand, CEO Says - (Financial Post via NewsPoints Desk)

  • Confusion about AstraZeneca's COVID-19 vaccine data and delays in Novavax' clinical trials are boosting global demand for Moderna's vaccine, as reported Financial Post on Wednesday.

  • Moderna CEO Stephane Bancel said governments around the world had approached his company seeking more supply of its vaccine.

  • AstraZeneca and its development partner, the University of Oxford, reported interim data last month that found its vaccine had prevented 70% of participants from falling ill, but said a lower initial dose of the vaccine, followed by a full dose, produced a 90% efficacy rate in a smaller set of participants, compared with 62% for two full doses.

  • "A lot of countries have realised that if they want vaccine in Q1 and maybe in Q2, they actually don't have six suppliers to go to, but they have two," he said, referencing Pfizer and BioNTech's comparable mRNA vaccine candidate.

  • Moderna has reached deals for supply with the US, the EU, the UK, Switzerland, Canada, Japan, Singapore, Qatar and Israel, among others.

  • Moderna anticipates being able to manufacture up to a billion doses of its vaccine in 2021.

To read more NewsPoints articles, click here.